Women achieved significantly reduced AngII sensitivity compared with men at lower dosages of irbesartan, suggesting men may require larger dosages for adequate RAS blockade.
Do men and women differ in their renal, systemic, and receptor responses to incremental doses of irbesartan?
Men may require larger dosages of angiotensin receptor blockers than women to achieve adequate RAS blockade of the renal microvasculature, and blood pressure response alone is an insufficient surrogate marker for this blockade.
Evidence suggests that gender differences exist in renin-angiotensin system (RAS) function. It was hypothesized that women may differ also in their response to RAS blockade. The renal and peripheral hemodynamic responses to incremental dosages of an angiotensin receptor blocker and the degree of angiotensin II (AngII) insensitivity achieved during 8 wk were examined in men and women. Participants were 30 young healthy men (n = 15; mean age 27 +/- 2) and women (n = 15; mean age 28 +/- 2) who were on a controlled sodium and protein diet for 1 wk before each study. The humoral, renal, and systemic response to incremental dosages of irbesartan (75 mg for 4 wk, then 150 mg for 4 wk) was assessed, as was the pressor response to AngII (3 ng/kg per min), at 2-wk intervals. AngII type 1 receptor expression in skin biopsies was assessed at baseline and after 8 wk by a real-time PCR protocol. Men and women both exhibited significant declines in BP. Women achieved significantly reduced AngII sensitivity compared with men at lower dosages, showing no pressor response at 4 wk of 75 mg/d irbesartan, whereas men continued to exhibit a pressor response at 4 wk of 150 mg/d. Receptor expression at baseline did not differ between men and women but by 8 wk was significantly decreased in women and unchanged in men. Our findings indicate that men may require larger dosages of angiotensin receptor blocker than do women and that the BP response cannot be used as a surrogate marker for adequate RAS blockade of the renal microvasculature.
Miller et al. (Thu,) conducted a other in Healthy (n=30). Irbesartan vs. Men vs Women was evaluated on Angiotensin II sensitivity and receptor expression. Women achieved significantly reduced AngII sensitivity compared with men at lower dosages of irbesartan, suggesting men may require larger dosages for adequate RAS blockade.